Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Odey buys £70m stake in biotech new boy

Odey buys £70m stake in biotech new boy

Hedge fund luminary Crispin Odey's investment boutique snapped up a large interest in Circassia Pharmaceuticals upon its initial public offering on 13 March.

Odey (pictured) bought 22.5 million shares in Circassia – a stake worth almost £70 million and equivalent to 12% of the business.

According to a filing on the London Stock Exchange, the holding is spread across a number of funds, with Crispin's Odey European fund holding 3.79% and all other funds holding less than 3%.  

The flotation of Oxford-based Circassia was the biggest in the UK’s biotech sector for decades, and at an initial launch price of £3.10 valued the firm at the very top of the expected range.

Circassia specialises in the development of allergy therapies, and it plans to use the proceeds from the listing to roll out its cat allergy treatment and develop other products for grass and dust-mite allergies.

It lost £20 million in 2013, but is now valued at almost £600 million.

'This is a milestone achievement in Circassia's history which demonstrates the significant progress we have delivered over the past seven years,' Circassia chief executive Steven Harris told the stockmarket last week. 

He added: 'We have been met with an enthusiastic response from investors across the UK, US and EU who have recognised the significant potential of our product portfolio and platform technology.

'As a result, we now have funds to bring Cat-SPIRE to market; the first of a new generation of allergy immunotherapy products that have the potential to overcome the limitations of current treatments.'

Odey’s firm, which he launched in 1991, oversees more than £7 billion of assets.

Crispin Odey personally runs a range of funds, including the Odey Pan European fund and is + rated by Citywire.

According to Citywire data, the fund has returned 32.8% over the past three years, compared with an average of 25.8% from his peer group.

He is also a renowned shorter of stocks, and among others is currently betting against Manchester United and Sainsbury’s.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Big City Bright Future

Big City Bright Future

Big City Bright Future, the brainchild of BlackRock, is a three-week work experience programme for school leavers looking to forge a career in the City.

Play Kames' Ennett: Trump good for US high yield, but beware Europe

Kames' Ennett: Trump good for US high yield, but beware Europe

Kames Capital’s head of high yield David Ennett believes the changing political landscape will be a positive for the US, but negative for Europe in 2017.

Play Philip Milburn: why inflation won't run out of control

Philip Milburn: why inflation won't run out of control

Kames bond fund manager views inflation as more of 'scare' than a 'problem' and is positioning his portfolios accordingly.

Read More
Your Business: Cover Star Club

Profile: change is the only constant for Quilter Cheviot

Profile: change is the only constant for Quilter Cheviot

This is not the first time we have profiled David Miller, but at the time of his previous appearance his company looked very different.

Wealth Manager on Twitter